Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03, FiscalAI reports.
Here are the key takeaways from Taysha Gene Therapies' conference call:
- All 33 treated patients cleared the acute post-dosing safety monitoring period, with no severe treatment-related serious adverse events or dose-limiting toxicities reported as of the November data cutoff. Management said TSHA-102 remains generally well tolerated across the trials.
- Taysha completed its BLA-enabling commercial-scale manufacturing campaign, with batches meeting predefined specifications and comparability criteria. The company said single-digit empty capsid levels and favorable yields could support product quality and efficient manufacturing, though it still plans to discuss the data and CMC strategy with the FDA.
- Taysha expects to report top-line results from the REVEAL pivotal trial’s six-month interim analysis and FDA feedback on the potential BLA pathway in the first half of 2027. Filing on six-month data could accelerate submission by at least two quarters, but the FDA has not yet agreed to that approach; the company said it would also share 12-month data.
- Taysha reported $422.8 million in cash and cash equivalents at September 30, which it expects to fund planned operations into the second half of 2028. Quarterly R&D and G&A expenses rose year over year, and net loss increased to $39.1 million from $32.7 million.
- The company said it has advanced launch preparations, including payer discussions, site readiness, and trade and distribution planning, and expects no supply constraint at launch. It also plans to nominate another CNS gene therapy candidate and begin preclinical work in the first half of 2027.
Taysha Gene Therapies Price Performance
TSHA traded up $0.09 during trading on Thursday, hitting $4.37. 1,154,769 shares of the stock traded hands, compared to its average volume of 3,082,836. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.76 and a quick ratio of 17.76. Taysha Gene Therapies has a twelve month low of $3.45 and a twelve month high of $7.30. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -10.49 and a beta of 1.36. The business has a 50 day moving average price of $4.55 and a 200 day moving average price of $5.29.
Analyst Upgrades and Downgrades
TSHA has been the subject of several analyst reports. The Goldman Sachs Group lifted their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of Taysha Gene Therapies in a research report on Monday, September 21st. Finally, Wolfe Research initiated coverage on Taysha Gene Therapies in a research report on Thursday, September 17th. They set an "outperform" rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $12.77.
Get Our Latest Stock Analysis on Taysha Gene Therapies
Taysha Gene Therapies Company Profile
(
Get Free Report)
Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company's lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha's research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.